FilingReader Intelligence
Sino Biopharmaceutical's cancer drug gets breakthrough designation
August 19, 2025 at 05:01 PM UTC•By FilingReader AI
Sino Biopharmaceutical Limited announced its LM-302 "CLDN18.2 ADC" was included in the Breakthrough Therapeutic Designation process by China's CDE. This innovative drug, developed by subsidiary LaNova Medicines, targets CLDN18.2-positive gastric and gastroesophageal junction adenocarcinoma.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
HKEX:1177•Hong Kong Exchange
News Alerts
Get instant email alerts when Sino Biopharmaceutical publishes news
Free account required • Unsubscribe anytime